Analyst Reco. Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
8.8 ^USD	+4.14%		+9.45%	+10.55%

May. 31	Nxera Pharma to Receive $4.6 Million Milestone Payments From Centessa Pharmaceuticals	MT
May. 13	Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Morgan Stanley Upgrades Centessa Pharmaceuticals to Equalweight From Underweight, Doubles Price Target to $8 From $4 on 'Encouraging' Preclinical Data on Narcolepsy Treatment Candidate	23-10-26	MT
Guggenheim Adjusts Price Target on Centessa Pharmaceuticals to $10 From $9, Maintains Buy Rating	23-08-15	MT
Goldman Sachs Adjusts Price Target on Centessa Pharmaceuticals to $5 From $4.50, Maintains Neutral Rating	23-08-15	MT
BMO Capital Adjusts Centessa Pharmaceuticals Price Target to $15 From $11, Maintains Outperform Rating	23-07-25	MT
Evercore ISI Initiates Centessa Pharmaceuticals at Outperform Rating	23-06-21	MT
Guggenheim Initiates Centessa Pharmaceuticals at Buy With $9 Price Target	23-06-12	MT
SVB Securities Initiates Centessa Pharmaceuticals at Outperform With $6 Price Target	23-03-17	MT
Morgan Stanley Adjusts Price Target on Centessa Pharmaceuticals to $4 From $5, Maintains Underweight Rating	23-01-24	MT
Morgan Stanley Double Downgrades Centessa Pharmaceuticals to Underweight From Overweight, Adjusts Price Target to $5 From $10	22-08-12	MT
BMO Capital Adjusts Centessa Pharmaceuticals' Price Target to $11 from $19, Keeps Outperform Rating	22-08-11	MT
Goldman Sachs Adjusts Centessa Pharmaceuticals' Price Target to $4 From $5, Keeps Neutral Rating	22-08-11	MT
Morgan Stanley Adjusts Price Target for Centessa Pharmaceuticals to $10 From $15, Maintains Overweight Rating	22-07-14	MT
BMO Capital Starts Centessa Pharmaceuticals at Outperform With $19 Price Target	22-06-17	MT
Goldman Sachs Adjusts Centessa Pharmaceuticals' Price Target to $8 from $12, Keeps Neutral Rating	22-05-24	MT
Morgan Stanley Adjusts Centessa Pharmaceuticals Price Target to $15 From $19, Maintains Overweight Rating	22-05-24	MT
Morgan Stanley Trims Centessa Pharmaceuticals Price Target to $19 From $20, Maintains Overweight Rating	22-04-05	MT
Goldman Sachs Starts Centessa Pharmaceuticals at Neutral, Maintains Price Target at $12	22-02-11	MT
Morgan Stanley Adjusts Centessa Pharmaceuticals' Price Target to $20 from $37, Keeps Overweight Rating	22-02-01	MT
CENTESSA PHARMACEUTICALS : Jefferies Starts Centessa Pharmaceuticals at Buy With $35 Price Target	21-06-22	MT
CENTESSA PHARMACEUTICALS : Morgan Stanley Starts Centessa Pharmaceuticals at Overweight With $37 Price Target	21-06-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Analyst Reco.

Filters